6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Neutropenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
10 O
% O
) O
were O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
10 O
% O
) O
were O
infusion O
reactions O
, O
neutropenia O
, O
thrombocytopenia O
, O
anemia O
, O
pyrexia O
, O
cough O
, O
nausea O
, O
and O
diarrhea O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
in O
Tables O
3-6 O
below O
are O
based O
on O
a O
safety O
population O
of O
773 O
previously O
untreated O
patients O
with O
CLL B-Not_AE_Candidate
. O

Patients O
were O
treated O
with O
chlorambucil O
alone O
, O
GAZYVA O
in O
combination O
with O
chlorambucil O
, O
or O
rituximab O
in O
combination O
with O
chlorambucil O
. O

The O
Stage O
1 O
analysis O
compared O
GAZYVA O
in O
combination O
with O
chlorambucil O
vs O
. O
chlorambucil O
alone O
, O
and O
Stage O
2 O
compared O
GAZYVA O
in O
combination O
with O
chlorambucil O
vs O
. O
rituximab O
in O
combination O
with O
chlorambucil O
. O

Patients O
received O
three O
1000 O
mg O
doses O
of O
GAZYVA O
on O
the O
first O
cycle O
and O
a O
single O
dose O
of O
1000 O
mg O
once O
every O
28 O
days O
for O
5 O
additional O
cycles O
in O
combination O
with O
chlorambucil O
( O
6 O
cycles O
of O
28 O
days O
each O
in O
total O
) O
. O

In O
the O
last O
140 O
patients O
enrolled O
, O
the O
first O
dose O
of O
GAZYVA O
was O
split O
between O
day O
1 O
( O
100 O
mg O
) O
and O
day O
2 O
( O
900 O
mg O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

In O
total O
, O
81 O
% O
of O
patients O
received O
all O
6 O
cycles O
( O
of O
28 O
days O
each O
) O
of O
GAZYVA-based O
therapy O
. O

Table O
3 O
Summary O
of O
Adverse O
Reactions O
Reported O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
1 O
) O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
GAZYVA O
+ O
Chlorambuciln O
= O
241 O
Chlorambuciln O
= O
116 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
69 O
21 O
0 O
0 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
41 O
35 O
18 O
16 O
Thrombocytopenia B-OSE_Labeled_AE
15 O
11 O
8 O
4 O
Anemia B-OSE_Labeled_AE
12 O
5 O
10 O
4 O
Leukopenia B-OSE_Labeled_AE
7 O
5 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
10 O
< O
1 O
7 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
10 O
0 O
7 O
< O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6 O
2 O
3 O
< O
1 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorder I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
< O
1 O
2 O
0 O
Table O
4 O
Summary O
of O
Adverse O
Reactions O
Reported O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
2 O
) O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
GAZYVA O
+ O
Chlorambuciln O
= O
336 O
Rituximab O
+ O
Chlorambuciln O
= O
321 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
66 O
20 O
38 O
4 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
38 O
33 O
32 O
28 O
Thrombocytopenia B-OSE_Labeled_AE
14 O
10 O
7 O
3 O
Leukopenia B-OSE_Labeled_AE
6 O
4 O
2 O
< O
1 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
9 O
< O
1 O
7 O
< O
1 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
10 O
2 O
8 O
< O
1 O
Constipation B-OSE_Labeled_AE
8 O
0 O
5 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
6 O
< O
1 O
3 O
0 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5 O
1 O
2 O
< O
1 O
Table O
5 O
Post-Baseline O
Laboratory O
Abnormalities O
by O
CTCAE O
Grade O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
1 O
) O
Investigations O
GAZYVA O
+ O
Chlorambuciln O
= O
241 O
Chlorambuciln O
= O
116 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
78 O
48 O
53 O
27 O
Lymphopenia B-OSE_Labeled_AE
80 O
40 O
9 O
3 O
Leukopenia B-OSE_Labeled_AE
84 O
37 O
12 O
< O
1 O
Chemistry B-NonOSE_AE
Hypocalcemia B-OSE_Labeled_AE
38 O
3 O
33 O
2 O
Hyperkalemia B-OSE_Labeled_AE
33 O
5 O
18 O
3 O
Hyponatremia B-OSE_Labeled_AE
30 O
8 O
12 O
3 O
AST B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
29 O
1 O
16 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
30 O
< O
1 O
20 O
2 O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
27 O
2 O
16 O
0 O
Hypoalbuminemia B-OSE_Labeled_AE
23 O
< O
1 O
15 O
< O
1 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
18 O
0 O
11 O
0 O
Hypokalemia B-OSE_Labeled_AE
15 O
1 O
5 O
< O
1 O
Table O
6 O
Post-Baseline O
Laboratory O
Abnormalities O
by O
CTCAE O
Grade O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
2 O
) O
Investigations O
GAZYVA O
+ O
Chlorambuciln O
= O
336 O
Rituximab O
+ O
Chlorambuciln O
= O
321 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
76 O
46 O
69 O
41 O
Lymphopenia B-OSE_Labeled_AE
80 O
39 O
50 O
16 O
Leukopenia B-OSE_Labeled_AE
84 O
35 O
62 O
16 O
Thrombocytopenia B-OSE_Labeled_AE
48 O
13 O
40 O
8 O
Anemia B-OSE_Labeled_AE
39 O
10 O
37 O
10 O
Chemistry B-NonOSE_AE
Hypocalcemia B-OSE_Labeled_AE
37 O
3 O
32 O
< O
1 O
Hyperkalemia B-OSE_Labeled_AE
14 O
1 O
10 O
< O
1 O
Hyponatremia B-OSE_Labeled_AE
26 O
7 O
18 O
2 O
AST B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
27 O
2 O
21 O
< O
1 O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
28 O
2 O
21 O
1 O
Hypoalbuminemia B-OSE_Labeled_AE
23 O
< O
1 O
16 O
< O
1 O
Infusion B-NonOSE_AE
Reactions I-NonOSE_AE
: O
The O
incidence O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
65 O
% O
with O
the O
first O
infusion O
of O
GAZYVA O
. O

The O
incidence O
of O
Grade O
3 O
or O
4 O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
20 O
% O
with O
7 O
% O
of O
patients O
discontinuing O
therapy O
. O

The O
incidence O
of O
reactions O
with O
subsequent O
infusions O
was O
3 O
% O
with O
the O
second O
1000 O
mg O
and O
< O
1 O
% O
thereafter O
. O

No O
Grade O
3 O
or O
4 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
were O
reported O
beyond O
the O
first O
1000 O
mg O
infused O
. O

Of O
the O
first O
53 O
patients O
receiving O
GAZYVA O
on O
the O
trial O
, O
47 O
( O
89 O
% O
) O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

After O
this O
experience O
, O
study O
protocol O
modifications O
were O
made O
to O
require O
pre-medication O
with O
a O
corticosteroid O
, O
antihistamine O
, O
and O
acetaminophen O
. O

The O
first O
dose O
was O
also O
divided O
into O
two O
infusions O
( O
100 O
mg O
on O
day O
1 O
and O
900 O
mg O
on O
day O
2 O
) O
. O

For O
the O
140 O
patients O
for O
whom O
these O
mitigation O
measures O
were O
implemented O
, O
74 O
patients O
( O
53 O
% O
) O
experienced O
a O
reaction O
with O
the O
first O
1000 O
mg O
( O
64 O
patients O
on O
day O
1 O
, O
3 O
patients O
on O
day O
2 O
, O
and O
7 O
patients O
on O
both O
days O
) O
and O
< O
3 O
% O
thereafter O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

Neutropenia B-NonOSE_AE
: O
The O
incidence O
of O
neutropenia B-OSE_Labeled_AE
reported O
as O
an O
adverse O
reaction O
was O
38 O
% O
in O
the O
GAZYVA O
treated O
arm O
and O
32 O
% O
in O
the O
rituximab O
treated O
arm O
, O
with O
the O
incidence O
of O
serious O
adverse O
events O
being O
1 O
% O
and O
< O
1 O
% O
, O
respectively O
( O
Table O
4 O
) O
. O

Cases O
of O
late B-OSE_Labeled_AE
- I-OSE_Labeled_AE
onset I-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
occurring O
28 O
days O
after O
completion O
of O
treatment O
or O
later O
) O
were O
16 O
% O
in O
the O
GAZYVA O
treated O
arm O
and O
12 O
% O
in O
the O
rituximab O
treated O
arm O
. O

Infection B-NonOSE_AE
: O
The O
incidence O
of O
infections B-OSE_Labeled_AE
was O
similar O
between O
GAZYVA O
and O
rituximab O
treated O
arms O
. O

Thirty-eight O
percent O
of O
patients O
in O
the O
GAZYVA O
treated O
arm O
and O
37 O
% O
in O
the O
rituximab O
treated O
arm O
experienced O
an O
infection B-OSE_Labeled_AE
, O
with O
Grade O
3-4 O
rates O
being O
11 O
% O
and O
13 O
% O
, O
respectively O
. O

Fatal O
events O
were O
reported O
in O
1 O
% O
of O
patients O
in O
both O
arms O
. O

Thrombocytopenia B-NonOSE_AE
: O
The O
overall O
incidence O
of O
thrombocytopenia B-OSE_Labeled_AE
reported O
as O
an O
adverse O
reaction O
was O
higher O
in O
the O
GAZYVA O
treated O
arm O
( O
14 O
% O
) O
compared O
to O
the O
rituximab O
treated O
arm O
( O
7 O
% O
) O
, O
with O
the O
incidence O
of O
Grade O
3-4 O
events O
being O
10 O
% O
and O
3 O
% O
, O
respectively O
( O
Table O
4 O
) O
. O

The O
difference O
in O
incidences O
between O
the O
treatment O
arms O
is O
driven O
by O
events O
occurring O
during O
the O
first O
cycle O
. O

The O
incidence O
of O
thrombocytopenia B-OSE_Labeled_AE
( O
all O
grades O
) O
in O
the O
first O
cycle O
were O
11 O
% O
in O
the O
GAZYVA O
and O
3 O
% O
in O
the O
rituximab O
treated O
arms O
, O
with O
Grade O
3-4 O
rates O
being O
8 O
% O
and O
2 O
% O
, O
respectively O
. O

Four O
percent O
of O
patients O
in O
the O
GAZYVA O
treated O
arm O
experienced O
acute O
thrombocytopenia B-OSE_Labeled_AE
( O
occurring O
within O
24 O
hours O
after O
the O
GAZYVA O
infusion O
) O
. O

The O
overall O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
and O
the O
number O
of O
fatal O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
similar O
between O
the O
treatment O
arms O
, O
with O
3 O
in O
the O
rituximab O
and O
4 O
in O
the O
GAZYVA O
treated O
arms O
. O

However O
, O
all O
fatal O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
patients O
treated O
with O
GAZYVA O
occurred O
in O
Cycle O
1 O
. O

Tumor B-NonOSE_AE
Lysis I-NonOSE_AE
Syndrome I-NonOSE_AE
: O
The O
incidence O
of O
Grade O
3 O
or O
4 O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
was O
2 O
% O
in O
the O
GAZYVA O
treated O
arm O
versus O
0 O
% O
in O
the O
rituximab O
treated O
arm O
. O

Musculoskeletal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Adverse O
events O
related O
to O
musculoskeletal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
all O
events O
from O
the O
System O
Organ O
Class O
) O
, O
including O
pain B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
the O
GAZYVA O
treated O
arm O
with O
higher O
incidence O
than O
in O
the O
rituximab O
treated O
arm O
( O
18 O
% O
vs O
. O
15 O
% O
) O
. O

Liver B-NonOSE_AE
Enzyme I-NonOSE_AE
Elevations I-NonOSE_AE
: O
Hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
have O
occurred O
in O
patients O
who O
received O
GAZYVA O
in O
clinical O
trials O
and O
had O
normal O
baseline O
hepatic O
enzyme O
levels O
( O
AST O
, O
ALT O
, O
and O
ALP O
) O
. O

The O
events O
occurred O
most O
frequently O
within O
24-48 O
hours O
of O
the O
first O
infusion O
. O

In O
some O
patients O
, O
elevations B-OSE_Labeled_AE
in O
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
were O
observed O
concurrently O
with O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
or O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

In O
the O
pivotal O
study O
, O
there O
was O
no O
clinically O
meaningful O
difference O
in O
overall O
hepatotoxicity B-OSE_Labeled_AE
adverse O
events O
between O
all O
arms O
( O
4 O
% O
of O
patients O
in O
the O
GAZYVA O
treated O
arm O
) O
. O

Medications O
commonly O
used O
to O
prevent O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
acetaminophen O
) O
may O
also O
be O
implicated O
in O
these O
events O
. O

Monitor O
liver O
function O
tests O
during O
treatment O
, O
especially O
during O
the O
first O
cycle O
. O

Consider O
treatment O
interruption O
or O
discontinuation O
for O
hepatotoxicity B-NonOSE_AE
. O

6.2 O
Immunogenicity O
Serum O
samples O
from O
patients O
with O
previously O
untreated O
CLL B-Not_AE_Candidate
were O
tested O
during O
and O
after O
treatment O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GAZYVA I-NonOSE_AE
. O

Of O
the O
GAZYVA O
treated O
patients O
, O
7 O
% O
( O
18/271 O
) O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
GAZYVA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
one O
or O
more O
time O
points O
. O

Neutralizing B-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
GAZYVA I-NonOSE_AE
antibodies I-NonOSE_AE
has O
not O
been O
assessed O
. O

Immunogenicity O
data O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
test O
methods O
used O
. O

Additionally O
, O
the O
observed O
incidence O
of O
a O
positive O
result O
in O
a O
test O
method O
may O
be O
influenced O
by O
several O
factors O
, O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
drug O
interference O
, O
concomitant O
medication O
, O
and O
the O
underlying O
disease O
. O

Therefore O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GAZYVA I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Clinical O
significance O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
GAZYVA I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
known O
. O

6.3 O
Additional O
Clinical O
Trial O
Experience O
Worsening B-NonOSE_AE
of I-NonOSE_AE
Pre I-NonOSE_AE
- I-NonOSE_AE
existing I-NonOSE_AE
Cardiac I-NonOSE_AE
Conditions I-NonOSE_AE
: O
Fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
GAZYVA O
. O

